Tests a decision aid for heart protection in cancer survivors
Tests a decision aid for heart care in adults with heart disease risk.
Plain-language title generated from the registry record
Registry title: PAtient Similarity for Decision-Making in Prevention of Cardiovascular Toxicity (PACT): A Feasibility Study
Key facts
- Where
- Milwaukee, United StatesSee the site
Where in United States
- Froedtert & the Medical College of WisconsinMilwaukee, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical College of Wisconsin
- Trial code
- NCT05377320
- Record updated
- 3 November 2026
- Original description
This is a single-center, double-arm, open-label, randomized feasibility study that will determine whether a novel clinical decision aid accessed via the electronic health record will be acceptable to both cancer survivors and their cardiologists, will favorably impact appropriate medication use and cardiac imaging surveillance, and will improve clinician and patient decision-making, perception, and behavior towards cardioprotective medication usage and cardiovascular disease imaging utilization.Read full original descriptionShow less
PAtient Similarity for Decision-Making in Prevention of Cardiovascular Toxicity (PACT): A Feasibility Study
This is a single-center, double-arm, open-label, randomized feasibility study that will determine whether a novel clinical decision aid accessed via the electronic health record will be acceptable to both cancer survivors and their cardiologists, will favorably impact appropriate medication use and cardiac imaging surveillance, and will improve clinician and patient decision-making, perception, and behavior towards cardioprotective medication usage and cardiovascular disease imaging utilization.
Inclusion: Patients ≥18 years with a history of cancer; Have not previously visited a cardiologist to assess cardiovascular risk after cancer diagnosis; Clinically at intermediate, high, or very high risk for cardiovascular diseases determined based on imprecise clinical risk models, such as those used for cardiac dysfunction; Ability to understand a written informed consent form, and willing to sign it prior to study registration.
Exclusion: Without a personal history of cancer; Existing cardiomyopathy diagnosed after cancer diagnosis; Documented cognitive impairment; Patient <18 years; Patient or patient representative who is unable and unwilling to sign the informed consent form.